別品名 |
Exisulind, 5-Fluoro-2-methy l-1-((4-(methylsulfonyl) phenyl)- methylene)-1H-indene-3-acetic acid
|
別包装 |
あり
|
純度 |
>=98%
|
分子量 |
372.41
|
CAS RN® |
59864-04-9
|
化合物の概要 |
NSAID; COX-1/2 and PDE inhibitor.
|
構造 |
C20H17FO4S
|
溶媒 |
Soluble in DMSO or ethanol.
|
使用目的 |
Sulindac is a non-steroidal anti-inflammatory drug (NSAID) that inhibits COX-1 and COX-2. Sulindac exhibits anti-inflammatory, tocolytic, neuroprotective, anti-metastatic, and anticancer chemotherapeutic activities. In vitro, sulindac inhibits phosphodiesterases (PDEs), increasing levels of cGMP and activation of PKG and inhibiting expression of β-catenin. In animal models of ischemic stroke, sulindac decreases infarct size and increases expression of Akt, Bcl-2, and HSP 27. This compound inhibits invasion of breast cancer cells and colon cancer cells by decreasing NF-κB-mediated transcription of several miRNAs. Additionally, sulindac downregulates expression of STAT3 and survivin and decreases cell proliferation and tumor growth in cellular and animal models of laryngeal cancer.
|
その他 |
[融点]248℃-250℃ [外観]Yellow powder
|
参考文献 |
Modi JP, Gharibani PM, Ma Z, et al. Protective mechanism of sulindac in an animal model of ischemic stroke. Brain Res. 2014 Aug 12;1576:91-9. PMID: 24968090.Li N, Xi Y, Tinsley HN, et al. Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling. Mol Cancer Ther. 2013 Sep;12(9):1848-59. PMID: 23804703.Li X, Gao L, Cui Q, et al. Sulindac inhibits tumor cell invasion by suppressing NF-κB-mediated transcription of microRNAs. Oncogene. 2012 Nov 29;31(48):4979-86. PMID: 22286762.Scheper MA, Nikitakis NG, Chaisuparat R, et al. Sulindac induces apoptosis and inhibits tumor growth in vivo in head and neck squamous cell carcinoma. Neoplasia. 2007 Mar;9(3):192-9. PMID: 17401459.
|
※サムネイル画像をクリックすると拡大画像が表示されます。
|
|
|
メーカー |
品番 |
包装 |
LKT
|
S8146
|
500 MG
|
※表示価格について
当社在庫 |
なし
|
納期目安 |
1週間程度
|
保存温度 |
常温
|
|